The foundation for the development of radiotherapeutics

In the field of cancer therapy, vectorized radiotherapy in nuclear medicine has not succeeded to found the momentum to show all its potential. In this domain, tens of thousands of patients could be cured if only the drugs (radiotherapeutics) that have already proven efficiency could have access to funds for completing their development. But nowadays investors are reluctant to take risk in this business they have difficulties to understand. The unique solution to bring these drugs directly to the patients within about three years would be to create a Foundation that would have sufficient budget to fill this target in the announced timeline. The reality of the situation, the real potential of the technology and the true advantages for the cancer patients is explained in these pages.

Cure of liver metastases from neuroendocrine pancreatic cancer after intraarterial peptide receptor radionuclide therapy (PRRNT) using Yttrium-90 (3 cycles) and Lutetium-177 (1 systemic course) somatostatin analogues more than 5 years after the first treatment was administered. (Courtesy of Prof. Dr. Richard P. Baum, Zentralklinik Bad Berka, Germany)

Comments are closed.